Amgen invests $300 million in Puerto Rico biologics plant as Novartis plans to close German oral drug factory
Amgen announced an additional $300 million investment in Puerto Rico to expand its biologics manufacturing capacity in Juncos, building on earlier commitments.
The funding will be used to upgrade facilities and increase production capabilities for biologic medicines, reinforcing Amgen's presence on the island.
Meanwhile, Novartis disclosed plans to exit its oral drug manufacturing site in Germany, signaling a shift in its European production footprint.
The move reflects a strategic realignment that could affect local employment and supply chains, while Novartis may redirect resources to other areas.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that